AVI BioPharma, ( Nachrichten ) Inc. (Nasdaq:AVII), today announced that its partner Global Therapeutics, a Cook Medical company, indicated in a press release today that results from animal studies using AVI ‘ s NEUGENE ® antisense drug AVI-5126 to prevent cardiovascular restenosis were “ highly promising.
More: continued here